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Chapter 1 
1 
Introduction  
1. Staphylococcus aureus  
In an elegant series of clinical observations and laboratory studies published in 
1880 and 1882, Ogston described staphylococcal disease and its role in sepsis and 
abscess formation. Staphylococcus aureus (S. aureus) is a Gram positive coccus 
and a member of the Micrococcaceae family. The name "aureus" is derived from 
characteristic gold pigmentation. On microscopical examination, the organisms 
appear as Gram-positive cocci in clusters [1] . The staphylococcal genome consists 
of a circular chromosome (of approximately 2800 bp) with prophages, plasmids, 
and transposons. Genes governing virulence and resistance to antibiotics are found 
on the chromosome, as well as in the extrachromosomal elements [2]. These genes, 
on the extrachromosomal elements, are usually transferred between staphylococcal 
strains, species, or other Gram-positive bacteria [3]. 
2. Antibiotic resistance in Staphylococcus aureus  
Meticillin-resistant S. aureus (MRSA) was discovered in 1960, within a year of the 
introduction of semi-synthetic anti-staphylococcal penicillins. Over the following 
40 years MRSA was a problem confined largely to hospitalized patients and to 
occasional outpatients who had readily identifiable predisposing risk factors, such 
as recent hospitalization, presence of an invasive device, history of surgery, 
haemodialysis or residence in a nursing home [4, 5].  
Invasive MRSA infections result in more deaths annually (~18,500) than any other 
single infectious agent in the United States, exceeding the number of deaths 
associated with HIV/AIDS, viral hepatitis and influenza combined [6]. MRSA 
infections are endemic in hospitals worldwide; in addition, community-associated 
MRSA (CA-MRSA) can cause infections in otherwise healthy individuals [7] and 
is responsible for a significant percentage of S. aureus skin and soft tissue 
infections in the United States (>50%), Asian countries (~17%) and Europe 
(ranging from <1% to 32%, depending on the country) [8, 9]. Unlike HA-MRSA, 
CA-MRSA is remarkably fit and able to spread within communities; it is virulent 
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and often susceptible to multiple narrow-spectrum antimicrobial agents. For 
example USA300 strain has emerged as the most prevalent CA-MRSA isolate in 
the United States and is commonly associated with skin and soft tissue infections 
[7].  
Resistance to methicillin, and in consequence to β-lactam antibiotics, is mediated 
by the mecA gene, which codes for the penicillin-binding protein 2A. The mecA 
gene is located on a genetic island called the staphylococcal cassette chromosome 
mec (SCCmec), differences in which are used to categorise MRSA. HA-MRSA 
strains carry SCCmec types I–III, whereas CA-MRSA strains carry SCCmec IV 
and the more recently isolated SCCmec [10]. Vancomycin resistance was first 
reported for Enterococcus faecium, and transfer of vancomycin resistance from 
enterococci to S. aureus has been shown to occur[11]. In 1996 a vancomycin 
reduced sensitivity strain of S. aureus was isolated. The first highly-vancomycin-
resistant strain was isolated in 2002. This strain was shown to carry a plasmid 
harboring, among other resistance genes, the vanA gene. The proteins encoded by 
these genes are responsible for replacing the C-terminal D-alanyl–D-alanine (D-
Ala–D-Ala) of the disaccharide pentapeptide cell wall precursor with a depsi- 
peptide, D-alanyl–D-lactate (D-Ala–D-Lac), thereby lowering the cell wall affinity 
for vancomycin [12].  
3. Virulence factors of Staphylococcus aureus  
Pathogenicity of S. aureus is caused by the expression of an arsenal of virulence 
factors which can lead to superficial skin lesions, such as styes, furunculosis, and 
paronychia, or to more serious infections, such as pneumonia, mastitis, urinary tract 
infections, osteomyelitis, endocarditis, and even sepsis. In rare cases S. aureus 
causes meningitis [13] (Fig. 1). 
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Fig. 1 The broad spectrum of S. aureus disease. Starting from benign 
colonization, throught increasingly more viulent and medically burdensome 
presentations. The degree of severity of these disease decreases from top to bottom 
of the triangle whereas the size of the affected population increases from top to 
bottom.  
 
Virulence factors that S. aureus employs to cause these diseases are displayed at 
the surface of the staphylococcal cell or secreted into host milieu [14]. Specifically, 
these virulence factors include: surface proteins that promote adhesion to and 
colonization of host tissues, invasins that are exported to an extracytoplasmic 
location and promote bacterial spread in tissues (leukocidin, kinases, and 
hyaluronidase), surface factors that inhibit phagocytic engulfment (capsule and 
protein A),  biochemical properties that enhance staphylococcal survival in 
phagocytes (carotenoid and catalase production), immunological disguises (protein 
A, coagulase, and clotting factor), membrane damaging toxins that disrupt 
eukaryotic cell membranes (hemolysins and leukotoxin), super-antigens that 
contribute to the symptoms of septic shock (SEA-G, toxic shock syndrome toxin 
[TSST], and ET) and determinants for inherent and acquired resistance to 
antimicrobial agents [15]. Staphylococci produce various enzymes, such as 
proteases, lipases, and hyaluronidases that destroy tissues. These bacterial products 
may facilitate the spread of infection to adjoining tissues, although their role in the 
pathogenesis of disease is not well defined.  
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Some of the key virulence associated factors are discussed in more details below. 
Capsule: More than 90% of S. aureus strains can produce in vitro capsular 
polysaccharide (CP), which can be divided into 11 serologically distinct capsular 
types, CP1 – CP11 [16]. The majority of isolates from different sources, are CP5- 
or CP8-positive. Expression of CP has been shown to enhance the bacterial ability 
to evade opsonophagocytosis, whereas CP-specific antibodies mediate type-
specific opsonophagocytosis and killing by polymorphonuclear cells. S. aureus 
capsules also promote abscess formation, animal studies suggest that the capsule 
promotes bacterial colonization and persistence on mucosal surfaces. Loss of 
capsule expression, however, may lead to S. aureus persistence in a chronically 
infected host. Experimental studies conducted with a mouse model of 
staphylococcal mastitis demonstrated that lack of capsular polysaccharide 
expression results in an increased capacity for persistence in the host. This capacity 
was attributed to more effective interaction between unmasked staphylococcal 
surface ligands and cell receptors, leading to internalization into epithelial cells 
[17]. CPs have been shown to be protective antigens in animal models, leading to 
their investigation as potential vaccine targets [18, 19].  
Protein A: Staphylococcal protein A (SpA) is a key virulence factor that enables S. 
aureus to evade innate and adaptive immune responses [20]. SpA is secreted as a 
precursor with an N-terminal signal peptide and a C-terminal LPXTG sorting 
signal [21]. SpA binds to the Fcγ portion of human and animal immunoglobulins, a 
defense mechanism that provides S. aureus with protection from opsonophagocytic 
killing. Previous works suggested that the mutated form of the protein SpAKKAA 
may be useful as a vaccine to prevent S. aureus disease in humans. SpAKKAA 
MAbs promoted opsonophagocytic killing of MRSA in mouse and human blood, 
provided protection from abscess formation, and stimulated pathogen-specific 
immune responses in the mouse model [22].  
Toxins: Staphylococci produce numerous toxins that are grouped on the basis of 
their action's mechanisms. Lysis of red blood cells is primarily mediated by the 
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hemolysins known as alpha (α), beta (β) and delta (δ) toxins. The α toxin encoded 
by the hla gene is important for S. aureus pneumonia, sepsis, septic arthritis, brain 
abscess and corneal infections[23, 24]. This pore forming toxin (33-kDa) is 
secreted by majority of S. aureus clinical isolates and is active against a wide range 
of mammalian cells. In addition to its pore forming ability, α toxin induces the 
release of cytokines and chemokines such as IL-6, IL-1β, IL-1α, IL-8, TNF-a, KC 
and MIP-2 [25-27]. Immunization with inactive α toxin was recently shown to 
protect mice against lethal S. aureus pneumonia [28]. Certain strains of S. aureus 
also secrete beta (β) toxin, a 35-kDa sphingomyelinase encoded by the hlb gene. In 
contrast to α toxin, β toxin is highly hemolytic for sheeps but not for rabbits 
erythrocytes. Delta (δ) hemolysin or toxin is a 26 amino acid peptide encoded by 
the hld gene [29]. This toxin is produced by 97% of S. aureus isolates and lyses 
erythrocytes, a variety of mammalian cells and sub-cellular structures such as 
membrane bound organelles, spheroplasts and protoplasts. In contrast to the α and 
β toxins, δ toxin does not possess a cleavable signal sequence, and its secretion 
mechanism is not completely understood. 
Phenol-soluble modulins (PSMs): PSMs are a family of amphipathic, a-helical 
peptides that comprise four shorter and two longer PSM-like peptides, whose genes 
are arranged in two gene clusters. Although the PSM genes are present in all 
sequenced S. aureus strains, much higher in vitro PSM production was detected in 
the CA-MRSA compared to HA-MRSA, raising the possibility that PSMs 
contribute to the enhanced virulence of CA-MRSA [30]. Within the past 5 years it 
has been demonstrated that PSMs have a variety of biological functions that are 
crucial to staphylococcal pathogenesis. Consequently, deletion mutants of the psma 
operon in S. aureus are severely attenuated in animal infection models, indicating a 
central role of PSM peptides in staphylococcal virulence [31]. Some studies 
revealed that all S. aureus PSMs are involved in different biological functions. 
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They efficiently lyse red and white blood cells, control biofilm development [32, 
33] and trigger receptor-mediated inflammatory responses [34]. 
4. Secretion systems in Staphylococcus aureus  
Staphylococcal proteins are exported thougth different secretion system that have 
been characterized experimentally or that can be deduced from sequenced 
genomes. Since these pathways are likely used for the export of virulence factors to 
the cell surface and the milieu of the host, can be regarded as a subcellular road 
map to staphylococcal pathogenesis. The secretion of proteins across biological 
membranes is in most cases mediated by translocation machinery recognising a 
specific sequence motif in the protein to be secreted [35]. 
The most commonly used pathway for bacterial proteins transport is the general 
secretory "Sec" pathway. Specifically, this pathway is responsible for the secretion 
of the majority of the proteins found in Bacillus subtilis, and other Gram-positive 
bacteria, including S. aureus. Proteins that are exported via the Sec pathway 
contain signal peptides with recognition sites for so called type I or type II SPases. 
Furthermore, the Sec-dependent export of proteins can be divided into the 
following three stages: I) targeting to the membrane translocation machinery by 
export-specific or general chaperones, II) translocation across the membrane by the 
Sec machinery, and III) posttranslocational folding and modification [15].  
Another well characterized secretion system is the twin-arginine translocation 
"Tat" pathway that exists in many bacteria, archaea, and chloroplasts. This pathway 
was named after the consensus double (twin) Arg residues that are present in the 
signal peptides[36] . In contrast to the Sec machinery, where only unfolded proteins 
are translocated across the membrane, the Tat machinery is capable of translocating 
folded proteins. In Gram-negative bacteria, an active Tat pathway seems to require 
three core components, named TatA, TatB, and TatC [37]. In all Gram-positive 
bacteria except streptomycetes and Mycobacterium smegmatis, the Tat pathway 
involves only TatA and TatC [38].  
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Type VII secretion system. Recent evidence shows that S. aureus has a novel and 
specialized secretion systems for the transport of extracellular proteins across their 
hydrophobic and highly impermeable cell wall [39]. The identification of this 
specialized secretion system began with the isolation of the tuberculosis vaccine 
strain Mycobacterium bovis Bacille Calmette-Guérin (BCG) at the Pasteur Institute 
(Lille, France) in 1921 [40]. This novel secretion secretion mechanism Type-VII 
secretion is responsible for the secretion of two highly immunogenic proteins: 
ESAT-6 (early secretory antigenic target) of 6 kDa and CFP-10 (culture filtrate 
protein) of 10 kDa protein. They are missing from the closely related attenuated 
live vaccine (BCG) due to the deletion of region of difference 1 (RD1) in which lie 
the two genes [41]. Strikingly, mycobacterial genomes encode five of these 
transport systems. Two of these systems ESX‐1 and ESX‐5, are involved in 
virulence: they both affect the cell‐to‐cell migration of pathogenic mycobacteria. 
ESX-3, a paralogous system present in all mycobacterial species, is required for 
growth in vitro. Was shown that mycobacteria lacking ESX-3 are defective in 
acquiring iron [42]. 
In Mycobacterium tuberculosis (M. tuberculosis), ESAT-6 (EsxA) and CFP-10 
(EsxB) belong to the WXG100 family of 23 small secreted proteins that share a 
size of approximately 100 amino acids, a helical structure, and a characteristic 
hairpin bend formed by the conserved Trp-Xaa-Gly (W-X-G) motif. The genes 
encoding these proteins, are called esx genes in M. tuberculosis (esxA-W) and are 
arranged in tandem pairs at 11 genomic loci. In five of these genomic loci (ESX-1–
ESX-5), the esx genes are flanked by genes coding for components of secretion 
machineries involved in the export of the corresponding Esx proteins [43]. 
ESX-1 components have been implicated in the ability of the bacterium to trigger 
macrophage production of IFN-β [44], activate the inflammasome, modulate 
macrophage cytokine production and signaling, and escape from the 
phagolysosome [45, 46]. The ESX-1 substrate proteins are also important targets of 
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the adaptive immune response and are recognized by both CD4
+
 and CD8
+
 T cells 
in a majority of infected individuals [47]. 
In addition to ESAT-6 and CFP-10, four other substrates of the ESX-1 locus have 
been reported in M. tuberculosis. This system includes a multi-transmembrane 
protein, Rv3877 (Snm4), and two putative SpoIIIE/FtsK adenosine triphosphatase 
(ATPase) family members, Rv3870 (Snm 1) and Rv3871 (Snm2). ESX-1 secretes 
also a transcriptional regulator, EspR (Rv3849) and two proteins of unknown 
function, EspA (Rv3616c) and EspB (Rv3881). EsxA, EsxB, EspA and EspB 
require each other for secretion[48]. 
The two proteins CFP-10 and ESAT-6 form a 1:1 complex. A striking feature of 
the complex is the long flexible arm formed by the C-terminus of CFP-10, which 
was found to be essential for binding to the surface of cells. The unstructured C-
terminus of the CFP-10 substrate was recognized by Rv3871, a cytosolic 
component of the ESX-1 system that itself interacts with the membrane protein 
Rv3870. Point mutations in the signal that abolished binding of CFP-10 to Rv3871 
prevented secretion of the CFP-10/ESAT-6 virulence factor complex.[49].  
Pallen et al. discovered ESAT-6 homologues in the sequenced genomes of other 
Gram-positive bacteria including Bacillus subtilis, Bacillus anthracis, Clostridium 
acetobutylicum, Listeria monocytogenes, and S. aureus[43]. The genes for the 
ESAT-6-like proteins are clustered with at least one gene encoding an FSD-type 
membrane protein, suggesting that FSD ATPases may represent a universal portal 
for excretion of Esx-like proteins (Fig. 2)[50].  
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Fig. 2 Comparison of different gene clusters that encode Type-VII secretion 
system 
 
S. aureus ESAT-6 secretion system. Protein sequence alignment of S. aureus EsxA 
and EsxB with M. tuberculosis Esx proteins show that M. tuberculosis and S. 
aureus EsxA display 20.8% identity and 25% similarity, whereas S. aureus EsxB 
and M. tuberculosis EsxA are 17.8% identical and 35% similar. The peptide 
sequences of S. aureus EsxA and EsxB encompass the WXG motif, a signature 
sequence of ESAT-6-like proteins [51] (Fig. 3A). It appears that both EsxA and 
EsxB carry the C-terminus translocation signal, which means that each protein is 
transported and acts independently as a virulence factor with no requirement for 
heterodimerization. It may be significant that the C-terminus of EsxA adopts a 
helical conformation, a structural feature that may be important in the molecular 
recognition of EsxA by the transport machinery. 
Unlike M. tuberculosis, S. aureus contains only a single Type-VII secretion sytem 
(Ess) gene cluster and EsxA and EsxB are encoded within a cluster comprised of 
eight predicted ORFs (esxA, esaA, essA, esaB, essB, essC, esxY, and esxB) as 
shown in Fig. 3B. 
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Missiakas et al., attributed a biological role to Esx proteins during staphylococcal 
infection and abscess formation. Mutants that failed to secrete EsxA and EsxB 
displayed defects in the pathogenesis of S. aureus murine abscesses, suggesting 
that this specialized secretion system may be a general strategy of human bacterial 
pathogenesis. Also they have shown that mutations in essA, essB, or essC, that are 
predicted encode for transmembrane proteins, abolished synthesis and therefore 
secretion of EsxA and EsxB without affecting transcription of esxA and esxB. 
Without secretion, EsxA and EsxB may be rapidly degraded in the bacterial 
cytoplasm or posttranscriptional feedback inhibition may reduce esxA and esxB 
expression [39]. Contrary to ESAT-6 and CFP-10 genes that are co-trascribed, 
altought esxA and esxB are located in the same locus, they are separated by 6 other 
genes and they are not co-trascribed. The esxA gene is under complex control. 
EsxA has been reported to be regulated by sigma factor B and σB-controlled 
SpoVG, and is a monocistronic transcript that is driven by a σA promoter. It was 
demonstrated that the transcription of esxA is controlled by a regulatory cascade 
involving downstream σB-dependent regulatory elements, including the 
staphylococcal accessory regulator SarA, the ArlRS two-component system and 
SpoVG. The regulation of EsxB is currently unknown [52]. 
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Fig. 3 A Sequence alignment of S. aureus EsxA and EsxB with ESAT-6 and CFP-
10 of M. tuberculosis. S. aureus EsxA shares 12% sequence identity with ESAT-6, 
14% with CFP-10, and 13% with S. aureus EsxB. EsxB shares 8% sequence 
identity with ESAT-6 and 13% with CFP-10. B esx locus in S. aureus C Membrane 
topology of Ess secretion system in S. aureus  
 
 
The crystal structures of EsxA was determined. The asymmetric unit of each 
crystal form is a dimer. The EsxA subunit forms an elongated cylindrical structure 
created from side-by-side α-helices linked with a hairpin bend formed by the WXG 
motif (Fig 4). Structural and sequence comparisons, exploiting biological data on 
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related proteins found in M. tuberculosis, suggest that this family of proteins may 
contribute to pathogenesis by transporting protein cargo through the secretion  
system exploiting a C-terminal signal that facilitate interactions with host receptor 
proteins[51].
A 
 
B 
 
C 
 
Fig 4. Structure of EsxA 
A A subunit of EsxA protein. The position of the conserved WXG motif is marked 
and Trp43 is depicted as black Van der Waals spheres. also the N- and C-terminal 
region are marked. B The electrostatic surface of EsxA protein (blu, positive; red, 
negative; white, neutral) show the hydrophobic side of the protein. C Similar 
representation rotated 180°C show the hydrophilic side of the protein. 
 
Secretion of EsxA and EsxB into culture medium during growth in vitro was 
demonstrated previously, with mutation of EsxB affecting secretion of EsxA and 
vice versa [39]. Very recent work further reports that deletions in either gene also 
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affects secretion of additional Ess substrates, EsxC and EsxD. EsxA and EsxB were 
reported to interact with different Ess substrates such as EsxC and EsxD 
respectively [53]. 
5. Staphylococcal Biofilms 
Staphylococci are recognized as the most frequent causes of biofilm-associated 
infections [54]. This exceptional status among biofilm-associated pathogens is due 
to the fact that staphylococci are frequent commensal bacteria on the human skin 
and mucous surfaces. S. epidermidis and S. aureus are the most frequent causes of 
nosocomial infections and infections on indwelling medical devices, which 
characteristically involve biofilms[55]. Often, S. aureus biofilm-associated 
infections are difficult to treat with antibiotics and devices need to be replaced [56]. 
In addition, they represent a reservoir for dissemination of infection to other sites in 
the human body. In contrast to many other medical biofilms, such as multi-species 
dental plaque formation, biofilm-associated infections with staphylococci are 
usually not mixed with other species . Research performed in many biofilm-
forming organisms has revealed that the development of a biofilm is a multi step 
process involving an initial attachment and a subsequent maturation phase and a 
final dispersal phase that involves the detachment of the bacterial cells, believed to 
be crucial for the dissemination of the bacteria [54] (Fig 5). 
 
Fig. 5 Schematic representation of development of a biofilm as a five-stage 
preocess. Stage1: Initial attachment of cells to a surface. Stage2: Production of 
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EPS resulting in more firmly adhered "irreversible"attachement. Stage3: Early 
development of biofilm architecture. Stage4: Maturation of biofilm architecture. 
Stage5: Dispersion of single cells from the biofilm.  
 
In the human body, the attachment to human matrix proteins represents the first 
step of biofilm formation. S. aureus express dozens of so-called MSCRAMMs 
(microbial surface components recognizing adhesive matrix molecules) that have 
the capacity to bind to human matrix proteins such as fibrinogen or fibronectin, and 
often combine binding capacity for several different matrix proteins. The 
subsequently phase is the maturation of biofilm formation is characterized by 1) 
intercellular aggregation that can be accomplished by a variety of molecules such 
as adhesive proteins or – usually polysaccharide-based - exopolymers, and 2) 
biofilm structuring forces that lead to the typical 3-dimensional appearance of 
mature biofilms with a fluid-filled channels. Biofilm detachment is crucial for the 
dissemination of bacteria to other colonization sites. It may occur by the 
detachment of single cells or larger cell clusters. Several factors may contribute to 
detachment: 1) mechanical forces, 2) cessation of the production of biofilm 
building material and 3) detachment factors sensu strictu [57]. It has long been 
recognized that biofilms have dramatically increased resistance to antibiotics. Two 
main mechanisms contribute to biofilm resistance: 1) prevention of the antibacterial 
substance from reaching its target and 2) the specific physiology of a biofilm, 
which limits the efficacy of antibiotics, mainly of those that target active cell 
processes and which may also include specific subpopulations of resistant cells. 
Recent studies of staphylococcal biofilm development have demonstrated that there 
are some key structural and regulatory factors that determine the form and 
physiology of staphylococcal biofilms.  
6. Intracellular life of Staphylococcus aureus 
In addition to its armor of virulence factors, the capacity of S. aureus to 
successfully evade host defenses has been recently attributed to its ability to invade 
immune and non-immune cells. S. aureus is mainly an extracellular pathogen, but 
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an accumulating number of studies have shown that it can invade and replicate in 
many types of host cells in vitro [58].  
This property potentially contributes to bacterial persistence and several benefits 
for the pathogen. It has been proposed that intracellular S. aureus evades exposure 
to antibiotics and host immunity [59]. Clinical studies have reported the presence 
of intracellular staphylococci from nasal epithelial cells, indicating that this could 
serve as a reservoir for recurrent infections[60]. The intracellular enviroment leads 
to the formation of small-colony variants (SCVs) characterized by slow growth and 
a range of morphological and metabolic changes including altered antibiotic 
resistance profiles [61, 62].  
The intracellular process of S. aureus is mediated by the interaction between 
fibronectin binding protein and host-cell α5β1integrin [63]. Other bacterial surface 
proteins like clumping-factor A or host cell Src kinase also appear important in the 
mediation of S. aureus uptake and intracellular persistence [64]. After 
internalization, the behavior of the bacterium varies according to cell-line or 
bacterial strain. In order to subvert host cell functions to their benefit, bacterial 
pathogens have developed various strategies. In particular, intracellular bacteria 
have adapted mechanisms to modulate the apoptotic pathway. The resulting 
induction or inhibition of apoptosis is often crucial for a successful infection of the 
host. Several bacteria elicit an inflammatory process which, in the place of 
infection, leads to the disruption of tissue barriers and thus may secure efficient 
microbial spread in the host [65].  
Some studies have reported an active intracellular bacterial replication within 
vacuoles. Others have described both a rapid bacterial escape from vacuole with a 
consequently induction of cellular apoptosis and persistence for several days before 
induction of escape processes[66].  
In the case of S. aureus the affected apoptotic pathways appear to depend on the 
strain and host cell type. Several studies reported that after infection the Cell Death 
Program occurs trought caspases activation [67-69]. During S. aureus infection the 
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production of α-toxin appears correlated with the induction of apoptosis[70]. In 
contrast, inhibition of apoptosis may be essential for intracellular pathogens to 
establish chronic infection. Pathogen-triggered anti-apoptosis of infected host cells 
facilitates a slow microbial replication process and enables persistence in the 
infected host. S. aureus was recently reported to induce anti-apoptotic factors in 
epithelial cells.  It seems, like  for many other bacteria, S. aureus may also be able 
to block apoptosis [71]. 
7. New therapeutic and vaccine strategies for Staphylococcus aureus 
treatment 
Mortality, morbidity, and cost from invasive S. aureus infections remain 
disturbingly high despite the introduction of several new antibiotics to treat 
methicillin-resistant S. aureus infections [72]. S. aureus infections are now the 
most common cause of hospitalization. To address these problems, investigators at 
universities, biotechnology companies, and large pharmaceutical companies have 
tried to develop an effective vaccine. Despite much effort, no clinical trials have 
succeeded to date. What has made S. aureus vaccine so difficult? First, the 
protective immunity against S. aureus is not completely understood and animal 
models, especially murine models, have not predicted success in humans as they 
did for the other successful vaccines. Second, the situation for S. aureus is much 
more complex, as this bacterium has multiple virulence factors that neutralize the 
host immune responses than these other bacterial pathogens. Third, S. aureus–
infected patients present with a very broad range of diseases, which means that 
vaccine development must focus on preventing a wide spectrum of disease 
presentations. The need for an effective S. aureus vaccine is increasing in view of 
broad antibiotic resistance and apparent increasing virulence of the community 
strains[73, 74]. 
Careful consideration of the patient populations in which candidate vaccines are 
initially evaluated for their efficacy will also play a key role for vaccine 
development. So far the vaccines tested in clinical trials targeted a single S. aureus 
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component. Studies using antigen combinations have shown greater efficacy than 
single antigen vaccines in animal models. Therefore, multivalent vaccines will 
likely work better in humans as well so that it is able to cover different pathologies 
that S. aureus causes. On this basis, Bagnoli et al. have proposed a model in which 
vaccine efficacy is gained through three major immune responses: 1) antibodies to 
directly inhibit bacterial viability and/or toxicity 2) antibodies mediated 
opsonophagocytosis 3) cell-mediated immunity to stimulate recruitment of 
phagocytes at the site of the infection. A combination of staphylococcal antigens 
with different properties and functions is able to elicit a potent antibody production, 
and a proper cellular response. In that way is possible to cover different pathologies 
caused by S. aureus infections [75]. 
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Outline of thesis 
Staphylococcus aureus is a versatile pathogenic bacterium capable of rapidly 
developing or acquiring multiple antibiotic resistances, and is now recognized as a 
global major health-care associated problem. S. aureus is responsible for a wide 
spectrum of human diseases, ranging from skin infections to severe diseases, such 
as rhinosinusitis, otitis, arthritis, osteomyelitis, endocarditis or fatal sepsis. 
These infections are difficult to eradicate and often relapse even after prolonged 
and adapted antibiotic therapy, suggesting that S. aureus has developed specific 
strategies for persistence such as the ability to live within biofilms or inside cells, 
and thereby evading antibiotics and immune responses. Due to the increasing 
antibiotic resistance, a new strategy for prevention the disease has become an 
important medical need.  
During my PhD I have focused my studies on the functional characterization of two 
secreted proteins, EsxA and EsxB secreted by the specialyzed ESAT-6 like 
secretion system. These proteins are important for virulence in murine infection 
during kidney abscess formation and they are considered as potential vaccine 
candidates. 
My research encompasses many areas including: 1) the genetic manipulation of S. 
aureus to understand the function of these proteins, 2) gene expression studies to 
explore environmental conditions under which the Esx proteins are induced, 3) the 
mechanisms invesigation of Ess-mediated secretion of EsxA and EsxB and finally 
4) the functional characterization of Esx proteins during intracellular 
staphylococcal infection in in vitro cellular models.  
Data from these studies will better characterize promising vaccine candidates and 
support development of an effective vaccine against S. aureus infection.  
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Introduction 
Staphylococcus aureus (S. aureus) a Gram-positive coccus, is a major human 
pathogen causes a wide spectrum of nosocomial and community-acquired 
infections that are associated with high morbidity and mortality [1]. It causes 
infections ranging from superficial skin lesions to serious conditions like 
pneumonia and endocarditis. Systemic and chronic infections, in particular, place a 
major burden on healthcare systems worldwide [2, 3].  
Treatment is made more difficult by the increasing number of MRSA, VRSA 
strains that are resistant to multiple antibiotics. One of the factors that contribute to 
staphylococcal resistance includes biofilm formation. Formation of biofilms or 
complex bacterial communities occurs in a multistep process and has been 
demonstrated to be important in staphylococcal virulence. Numerous reports in the 
past two decades have shown that especially biofilm-forming staphylococci cause a 
severe infections [4]. Biofilm formation by pathogenic staphylococci on implanted 
medical devices leads to “chronic polymer-associated infections”. Bacterial cells in 
a biofilm have been reported to alter metabolic activity [5, 6].  
S. aureus pathogenicity is multifactorial and depends on the expression of a large 
class of gene products comprising cell-wall associated and extracellular proteins. 
These secreted virulence factors including enzymes and toxins are commonly 
exported by the Sec secretion system, a well-described secretion pathway [7]. An 
Ess secretion system similar to the Type-VII secretion system of M. tuberculosis 
was reported in S. aureus [8]. The ESAT-6 secretion system (Ess) consists of 12 
proteins, including EsxA and EsxB that are similar to the ESAT-6 and CFP-10 of 
M. tuberculosis. ESAT-6 (EsxA) and CFP-10 (EsxB) are well-characterized 
virulence factors of M. tuberculosis [9].  
The Esx substrates are typically small proteins (100 amino acids) with a conserved 
WXG motif. These WXG100 proteins are a class of effector molecules found in 
other Gram-positive bacteria. Bioinformatic analyses have shown that one WXG 
gene is frequently positioned near, or directly adjacent to a second related WXG 
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gene [10]. The identification of WXG proteins encoded by the pathogens M. 
tuberculosis and S. aureus has created significant interest in the proteins biological 
activity.  
EsxA and EsxB factors, secreted by the system, are well conserved across clinical 
S. aureus strains and are currently being considered as potential vaccine candidates. 
Although well conserved between strains, expression and secretion of Ess-encoded 
substrates are poorly studied, both in vitro growth and during human 
staphylococcal infection. While the mycobacterial Esx proteins are important in 
several host-associated functions such as cell survival and granuloma formation[11, 
12], the biological functions of the S. aureus Esx proteins are however not known 
and the mechanism of action during the pathogenesis is still unclear. Missiakas et 
al. have showed that EsxA, EsxB and other Ess proteins are important during 
kidney abscess formation in a murine infection and that some of the Ess proteins 
are important for bacterial persistence in a staphylococcal abscess [8, 13]. 
In M. tuberculosis the Esx substrates ESAT-6 and CFP-10 were shown to interact 
each other and form a 1:1 complex [14]. A striking feature of the complex is the 
long flexible arm formed by the C-terminus of CFP-10, which was found to be 
essential for the secretion [15] and for binding to the surface of cells strongly 
suggest a key signalling role for the complex, in which the binding to cell surface 
receptors leads to modulation of host cell behaviour to the advantage of the 
pathogen [14].  
The structure of the S. aureus secretion apparatus or the mechanisms of Esx protein 
secretion are still unclear. The interactions between the various Ess components 
have not yet been mapped completely.  
Sundaramoorthy et al. reported that EsxA and EsxB purified from E. coli do not 
form a complex. They obtained crystals of EsxA and there are no current evidence 
that the two proteins could interact each other [16]. Recent study shown that EsxB 
associates with a novel substrate, EsxD, and EsxA dimerizes with itself or EsxC 
(EsaC). In particular EsxA and EsxC form both homo- and heterodimers whereas 
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EsxB and EsxD appear to function as a heterodimer [17]. EsxD carries the C-
terminal motif YxxxD/E that has been proposed to target Type VII substrates for 
secretion in mycobacteria [18]. Was shown that the deletion, in this motif prevent 
secretion of EsxA and EsxC but not EsxB or EsxD [19]. The genetic inactivation of 
esxA, esxB, esxC or esxD leads to loss of secretion of all four substrates. Moreover 
the deletion of esxD abrogated the production of EsxB altogether and affected the 
secretion, but not the production, of EsxA and EsxC.  
Identifying all the bacterial interactors of the Esx proteins would help to understand 
how the secretion apparatus function. Futhermore, identification host proteins that 
may interact with these proteins could indicate a role in host-pathogen interactions. 
In this study genetic and biochemical approaches were used to characterize the Esx 
proteins of S. aureus in order to better understand their mechanisms of action 
during staphylococcal infection.  
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Material and methods 
1. Bacterial RNA extraction and qRT-PCR  
Over night (O/N) cultures were diluted (1/100) in 5ml of TSB and grown until 
specific OD600. Cells were sedimented by centrifugation, suspended in TSM (100 
mM Tris·HCl, pH 7.0/500 mM sucrose/10 mM MgCl2) and digested with 
lysostaphin (5µg/ml) for 5 min. The resulting protoplasts were suspended with 
RLT buffer and RNA was isolated using the Qiagen RNeasy mini kits (Qiagen) 
using manufacturer’s protocol. For intracellular bacterial RNA extraction, after 
infection of cells total RNA was extracted with TRIzol (1ml/well) (Life 
Technologies) and purified using Zymo Quick RNA purification Kit (The 
Epigenetics Company). Followed by on column DNase I treatment (Qiagen) and 
then DNase I treatment in solution (Roche). Reverse transcription was performed 
using Superscript II (Invitrogen). Real-time PCR was done using TaqPlatinum 
Syber Green polymerase SuperMix UDG (Invitrogen). A relative quantification 
was performed using 16S rRNA as internal control. Primers used for qRT-PCR are 
listed in the table 1.  
Primers Sequence 
qRTesxA FW  AGGTGAAATTGCAGCGAACT 
qRTesxA RW  CTTGTTCTTGAACGGCATCA 
qRTesxB FW  AGCGGCAAAAACAGCTAAAG 
qRTesxB RW  TATTGGCGAACTGTCCTTCC 
qRT16S FW TACGGCTTACCAAGGCAAC 
qRT16S RW CGGAAGATTCCCTACTGCTG 
! 
Table 1: Sequence of qRT-PCR primers specific for esxA, esxB and 16S.  
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2. Construction of bacterial mutants 
For deletion of esxA and esxB a 2-kbp DNA fragments flanking the esx genes were 
amplified by PCR and cloned into the Escherichia coli/S. aureus shuttle/suicide 
vector pKOR1 [20] with abutted XhoI restriction sites and att site using primers
listed in the table 2. Constructs containing flanking genomic regions of esxA and 
esxB were cloned first in E. coli then into RN4220 (restriction negative, 
methylation positive strain). Plasmid DNA extracted was used to transform S. 
aureus USA300 MRSA. Integration of plasmid into the chromosome was obtained 
at non permissive conditions for pKOR1 replication (incubation twice at 43°C in 
TSB) and the selection for homologous recombination and pKOR1 integration into 
the bacterial chromosome was induced by growing bacteria at permissive 
temperature (incubation twice 2 at 30°C in TSB). Anhydrotetracycline-mediated 
induction of pKOR1- encoded secY antisense RNA which inhibits growth was 
used for selecting for chromosomal excision and loss of plasmid at 30°C. 
Primers Sequence 
esxA flanking region 1 FW  GGGGACAAGTTTGTACAAAAAAGCAGGCTTAAAATTGATCCTCGTGTTG  
esxA flanking region 1 RW  GAGAGAC TCGAGAACTAGAAACCTCCTGAAT  
esxA flanking region 2 FW  GAGAGACTCGAGGC ATTCTGAAATTGGCAAAG  
esxA flanking region 2 RW  GGGGACCACTTTGTACAA GAAAGCTGGGTGTATC TTGCATACTTGATTG  
esxB flanking region 1 FW  GGGGACAAGTTTGTACAAAAAAGCAGGCTCAGCAATGATTTCATCAGAA  
esxB flanking region 1RW  GAGAGACTCGAGCATATCTTCACCTCAATATTAAT  
esxB flanking region 2 FW  GAGAGACTCGAGTGAAAGATGTTAAGCGAAT  
esxB flanking region 2RW  GAGAG AATGCTCGAGAACCCATGATGAAAGATGTTAAGCGAAT  
 
Table 2. Sequence of primers for knoching out esxA and esxB gene. 
For complementation of mutant strains, the full length esxA and esxB genes were 
amplified using specific primers for the esx genes and cloned into plasmid 
pOS1CK, which was generated by cloning the P1 constitutive promoter of the sarA 
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gene into the pOS1 plasmid. For complementing with both genes, esxB was cloned 
downstream of esxA in the pOS1CKesxA construct. For site direct mutagenesis of 
esxA the leucine, serine double mutations were introduced into the esxA gene 
cloned into a pET vector by PIPE [21]. To create the mutations in glycine95 we 
used primers carrying the mutated amino acid sequence. esxA truncated gene was 
amplified using primers listed in the table 3. All mutant forms were cloned into the 
episomal plasmid pOS1CK. 
Primers Sequence 
esxALSGFW:  GCGCTGCAGTT 
GAGAGGAGAGAAAATGGCAATGATTAAGATG  
esxALSGRW:  GCGCCCGGTTATTGCAAAC CGAAATTAT  
esxAtruncFW  GCGCTGCAGCCGCTCGAGATGGCAATGATTAAG  
esxAtruncRW  TCCCCCGGGTTGTTGGTCTTGTTC  
 
Table 3: Sequence of primers for esxA mutation  
3. Tandem Affinity Purification (TAP)-Tagging and Pull Downs  
esxA/B gene was cloned in-frame with the two tags: FLAG protein and the 
Streptavidine Binding Peptide (SBP) at N- and C-terminus into episomal plasmid 
pAM401. ∆esxA or ∆esxB, were transformed with the plasmid. As negative control 
the same strains were transformed with empty plasmid. After growing the bacteria 
until late log phase, the total extracts were prepared using buffer containing 
lysostaphin 5ug/ml, 10mM HEPES, 150 mM NaCl pH 7.5, 0.4% NP40 and 
complete protease inhibitor. The affinity pull down was performed as described in 
Schluepen et al. article [22]. After binding of the EsxA-SBP-FLAG to the 
streptavidine beads the sample were washed using stringent solution and after the 
elution step performed with biotin, the purified complex was subjected to SDS-
PAGE. The sample was trypsin-digested and analyzed by LC-MS/MS in PPI group 
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in Novartis. Anti-FLAG immunoblotting was used to verify the presence of the 
flagged EsxA protein. 
4. Preparation and analysis of bacterial fractions 
Bacterial lysates and supernatants were prepared as modification of described 
previously [23]. Bacterial strains were grown O/N from glycerol stocks in TSB at 
37°C with shaking. Cultures were diluted 1:100 in fresh broth and shaken at 37°C 
until they reached an OD600 1. For whole culture lysates, 5ml of cultures were 
centrifuged, washed once with PBS and suspended 1ml di Tris-HCl pH 6.8 with 
protease inhibitors and incubated in the presence of lysostaphin (Sigma) at a final 
concentration of 100µg/ml for 1h at 37°C at 750 rpm, followed by freezing/thawing 
three times in a dry ice/thermomixer at 37°C. The bacterial lysates were 
centrifuged at 14,000 rpm for 10 min, the supernatants were filtered and the 
proteins in the lysates were precipitated with TCA at final concentration of 10%. 
5. Biofilm formation in vitro 
To reproduce biofilm in vitro, bacteria grown in a rich medium BHI supplemented 
with 1% glucose and 3% NaCl at different time points: 6, 12, 24, 48 and 72h at 
37°C and in 5% of CO2 rich environment without shaking in a 24 well plate. 
Biofilm formation was made visible by staining S. aureus cells with 0.2% of crystal 
violet for 15 minutes. After three washes biofilm was quantified by measuring OD 
at540nm. 
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Results  
1. Gene expression analysis for esxA and esxB 
1.2 Quantitative Real Time PCR in different in vitro conditions 
In order to better identify the molecular mechanisms of action of esxA and esxB it 
was necessary first define the conditions in which esxA and esxB are expressed. 
Previous studies involving the analysis of expression of virulence factors were 
mainly performed in vitro during growth in rich medium [24]. However, when S. 
aureus infects a host, the bacterial growth conditions are quite different from those 
in a medium, which may be related to the different expression of virulence factors 
in the host [24]. It has been previously reported that stress conditions, such as 
growth in presence of serum, CO2, anaerobic conditions and biofilm are 
responsible for the induction of different virulence factors [24]. 
In this study we investigated the expression of esxA and esxB during different 
phases of growth, in presence of serum, during biofilm formation and within 
eukaryotic cells after in vitro infection using quantitative real-time PCR.  
We compared the expression of esxA and esxB in two relevant clinical isolate 
Newman a meticillin sensitive strain (MRSS) and USA300 a meticillin resistent 
strain (MRSA) during growth in rich medium Tryptic Soy Broth (TSB). The result 
obtained shown an increase of transcript levels for both genes in USA300 in 
comparison to Newman strain (Fig. 1A).  
Then we investigated the expression kinetics of the esxA and esxB genes. We 
extracted the bacteria RNA at early, late and stationary phase. The data, normalized 
to expression during early phase showed that esxA is expressed more during the 
late phase of growth (Fig. 1B). 
Since is known from literature that many virulence factors, are significantly 
increased during growth in serum compared to that in bacterial medium, we 
investigated the same hypotesis for esxA and esxB expression. We quantified the 
level of transcript of esxA and esxB during growth in DMEM medium 
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supplemented with different concentration of Fetal Bovine Serum (FBS) 2%, 10% 
and 20%. The bacterial RNA was extracted at late log phase and the data were 
normalized to transcript levels measured during growth in DMEM medium. The 
result showed that the transcript levels of esxA and esxB decrease in medium 
supplemented by 2-20% of serum (Fig. 1C). The biofilm-forming ability is an 
attribute of several pathogens. In particular S. aureus is one of the most frequent 
cause of biofilm-related infections [4]. A comparative S. aureus global gene 
expression transcriptome analysis has shown several genes differentially expressed 
under biofilm formation in comparison to planktonically growth[6]. In order to test 
if our genes could be expressed in biofilm, we set up an in vitro biofilm assay 
where the bacteria grow in a rich media Brain Heart Infusion broth (BHI) 
supplemented with 1% of glucose and 3% of NaCl. We detected an increase in 
expression of esxB gene after 24h of biofilm growth in static condition compared to 
planktonic growth after 24h of incubation at 37°C (Fig. 1D). 
A transcriptome analysis by Garzoni et al. shows an extensive alteration of 
bacterial gene expression following internalization of epithelial cells [25]. These 
findings suggest that S. aureus extensively reprograms its transcriptome to adjust 
the intracellular environment. As the mycobacterial Esx proteins are known to 
function intracellularly [12], we wanted to investigate if esxA and esxB are 
differentially expressed when S. aureus is within eukaryotic cells. In order to study 
this, we set up an in vitro infection assay where A549 human lung epithelial cells 
were infected with USA300 strain (as described in Methods of the fourth chapter of 
the thesis). RNA was extracted from intracellular bacteria 6h after infection (p.i.). 
Quantitative real time PCR analysis for esxA and esxB showed that both genes, in 
particular esxB, are up-regulated upon internalization when normalized to 
expression in the infection medium, DMEM with 10% FBS (Fig. 1E). 
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Fig. 1 Gene expression analysis for esxA and esxB genes by quantitative real-
time PCR (qRT-PCR). 
A Expression analysis of esxA and esxB genes in different strains Newman and 
USA300 and B in different growth of phases during growth in TSB medium: early, 
late and stationary. C esxA and esxB transcripts level from DMEM plus fetal 
bovine serum. D Expression during biofilm formation and E upon internalization 
of epithelial cells 6h post infection. A relative quantification was performed using 
16S rRNA as internal control. * indicates significant differences as compared with 
reference control condition (P< 0.05). The data presented are the mean of 3 
independent experiments +/- s.d. in all the experiment. Data shown in C are 
representative of 2 independent experiments. 
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2. Generation and characterization of esx mutants  
2.1 Generation of deletion mutants 
In order to characterize the functions of EsxA and EsxB we made unmarked, single 
deletion mutants for esxA and esxB genes in two relevant clinical isolates of S. 
aureus, Newman (MSSA) and USA300 (MRSA) strains. To create deletion of 
these genes in the genome of S. aureus we used pKOR1, an Escherichia coli/S. 
aureus shuttle/ suicide vector that permits rapid cloning via lambda recombination 
and ccdB selection (Fig 2A). A method for rapid selection of allelic replacement 
mutations in the chromosome of S. aureus was described by Bae et al. [20]. 
Staphylococci were transformed and grown at 43°C, a non-permissive condition for 
pKOR1 replication that allows the selection for homologous recombination and 
plasmid integration into the bacterial chromosome. Anhydrotetracycline-mediated 
induction of pKOR1-encoded secY antisense transcript via the Pxyl/tetO promoter, 
a condition that is not compatible with staphylococcal growth, selects for 
chromosomal excision and loss of plasmid. Using this strategy, allelic replacements 
in S. aureus were generated at frequencies that obviated the need for antibiotic 
marker selection (Fig. 2B).  
In order to characterize the function of both proteins, double mutant for esxA and 
esxB was generated in both strains. ∆esxA genetic background was used to make 
deletion in esxB gene. ∆esxA competent cells were transformed using the same 
strategy describe before.  
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Fig. 2 pKOR1 allelic replacement generates staphylococcal chromosomal 
deletions 
A pKOR1 vector map. B Chromosomal map of esxA/B gene and the location of 
PCR primers to make esx deletion constructs. The location of primers (attB1-
esxAB-FW and attB2- esxAB-RW) are shown as short black arrows.  
 
The mutants were confirmed by PCR using two different sets of primers: one 
annealing to the flanking region of esxA or esxB gene and the other specific for 
each gene. As shown in Fig 3A we verified the different size of fragment around 
the esx gene for mutant (2Kb) compared to WT (2.5Kb) and the lack of esxA and 
esxB (Fig. 3A). The lack of the protein was verified by western blot analysis (Fig. 
3B). The deletion was further confirmed by qRT-PCR and sequencing. 
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Fig. 3 Genetical and biochemical analysis of esxA, esxB and esxAB deletion 
mutants 
A PCR was performed on chromosomal DNA from WT and ∆esxA, ∆esxB or 
∆esxAB mutants using primers specific for flanking region of esx gene or binding 
to the esx genes. PCR products were analyzed on 0.8% agarose gel. The expected 
size for PCR products from genomic DNA obtained from the WT or mutant strains 
is 2.5 or 2 Kb, respectively. B Western blot analysis anti-EsxA on total extract of 
WT and esx mutants generated in two different strains USA300 and Newman.  
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3. Characterization of esx mutant strains during biofilm formation 
3.1 Role of Esx proteins in staphylococcal biofilm 
It is reported in a previous transcriptome analysis on S. aureus biofilms that several 
virulence factors are differentially expressed during biofilm formation [4] and our 
gene expression analysis showed an up-regulation of esxB gene in biofilm. Hence 
we wondered if these two small proteins could have a role during biofilm 
development. We investigated the behavior of the esx deletion mutants in an in 
vitro biofilm assay. We found that, although the mutants have no growth defects in 
BHI medium (Fig. 4A), a reproducible 1.5-2 fold increase in biofilm formation for 
the esxB deletion mutant as compared to WT strain at later time point (Fig. 4B, C). 
No differences were detected at early time points 6 and 12h after incubation. 
Our hypothesis is that EsxB protein could play a role at later steps of biofilm 
development, i.e during the dispersal phase of staphylococcal biofilms.  It could be 
directly involved in biofilm detachment by affecting cell-cell interactions or it 
could act to destroy the biofilm matrix. It is also possible that EsxB plays indirect 
role acting as a transcriptional regulator (up-regulates proteases, adhesins etc.), or 
by controlling post-translationally the secretion of proteins that may be involved in 
biofilm formation.  
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Fig. 4 esx mutants do not display any in vitro growth defects in media tested; 
increase of biofilm formation for esxB and esxAB at later time points  
A Growth curves of WT and the various esx mutants in Brain Heart Infusion + 
1%glucose, 3%NaCl at 37°C with shaking B Image showing biofilm formed by 
WT Newman and USA300 S. aureus strains and the various esx mutants after 24h 
in BHI containing NaCl and glucose at 37°C in 5% CO2 and stained with 0.2% 
crystal violet C A reproducible 2-fold increase in biofilm accumulation was 
observed for the ∆esxB mutants as compared with the WT at later time points. * 
indicates significant differences as compared with WT (P< 0.05). The data are 
representative of 3 independent experiments. 
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3.2 Transcriptome analysis of esx mutants 
The mycobacterial ESX-1 substrate EspR is known to regulate the expression on 
other esx genes [26]. It is possible that the staphylococcal Esx proteins may have 
regulatory roles, which may mediate the effects observed above in biofilm 
formation. In order to investigate if EsxA and EsxB have a role in regulating the 
expression of other S. aureus factors, we performed a comparative gene expression 
analysis between WT Newman strain and various esx deletion mutants using S. 
aureus oligonucleotide microarrays.  
Microarrays were first validated using various genomic DNA and RNA controls. 
Gene expression analysis showed no significant differences in the expression 
profiles of WT and esx mutant during growth in BHI.   
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4. Characterization of the Esx proteins secretion mechanisms  
4.1 Interactions between Staphylococcus aureus Esx components  
Interactions between staphylococcal Esx components and mechanisms by which 
they mediate secretion of substrates are not clear, very recent work further reports 
that deletions in either gene also affects secretion of additional Ess substrates [19]. 
The homologues mycobacterium Esx proteins ESAT-6 and CFP-10 was shown to 
be secreted as an heterodimer and function only when interacted each other and 
with other ESX-1 components. In order to investigate the proteins that interact with 
EsxA and EsxB, we used in vitro pull down approach. We employed a Tandem 
Affinity Purification (TAP) method in combination with mass spectrometry to 
identify possible interactors of EsxA and EsxB. This method is based on the 
sequential utilization of two different affinity tags to purify protein assemblies [22]. 
esxA and esxB genes were cloned in frame with a dual tag: a streptavidin binding 
protein plus a FLAG-peptide epitope at either the N- or the C-terminus of the 
proteins, and expressed in ∆esxA and ∆esxB (Fig 5A). Eluates from the respective 
affinity purifications were analysed by western blot showing only the C termed 
FLAG tag EsxA protein (Fig 5B, C). EsxB- FLAG was not detected probably due 
to the probable tag cleavage. However when we analysed the eluates by Mass 
Spectrometry analysis we did not identify any S. aureus proteins that directly 
bound to EsxA. This might be because the conditions under which the pull downs 
were performed were not suitable to allow stable interactions.  Also, it is possible 
that the presence of a FLAG tag in these small proteins could interfere with the 
interactors binding to the proteins.  
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Fig. 5 TAP-tag Pull down   
A Schematic representation of TAP-tagged esx gene constructs. B Schematic 
representations of TAP tag pull down of interacting proteins. C Western blot 
analysis to detect FLAG-tagged protein. A: unbound fraction B: eluate fraction 
after pulling down total lysate with anti-FLAG antibody Lines 1 and 3: ∆esxA 
expressing EsxA-FLAG protein. Lines 2 and 4: negative control, ∆esxA-empty 
plasmid.  
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4.2 Secretion of EsxA 
The homologues mycobacterial EsxA and EsxB proteins are secreted thought the 
Esx secretion system with non–classical signal sequence. As the signal sequences 
controlling S. aureus Esx protein secretion are not known, we wanted to determine 
the residues that are required for secretion of the protein in vitro. Based on the 
homology between M. tuberculosis and S. aureus Esx proteins, we identified amino 
acids (a.a.) conserved between the proteins at the C-terminus: leucine90, serine91 
and glycine95 (Fig. 6A). EsxA bearing mutations in 3 a.a. or with a C-terminal 8 
a.a. deletion were expressed episomally in the ∆esxA mutant to create strains 
∆esxApOS1CKesxA-LSG (∆esxA-esxALSG) and ∆esxApOS1CKesxAtrunc (∆esxA-
esxAT) respectively. Immunoblotting analysis showed that the triple mutation in 
EsxA reduced the secretion of the protein into the culture supernatant while 
truncation of the C-terminal tail of EsxA severely impaired secretion of the protein 
compared with secretion of native EsxA (Fig. 6B, C). 
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Fig. 6 C-terminal residues are important for secretion of EsxA 
A Alignment of amino acid sequence of M. tuberculosis and S. aureus EsxA and 
EsxB proteins. In red are shown the high conserved residues that were replaced 
with alanine and the blue line indicates the 8 a.a deleted in the truncated EsxA 
protein. B Immunoblotting analysis of total extracts (TE) and supernatants (SN). 
Proteins in each fraction were precipitated with TCA, separated on SDS-PAGE, 
and detected by immunoblotting with anti-EsxA and anti-Hemolysin (loading 
control). Loading was normalized by OD600 of bacterial culture. C The graph 
shows the densitometry analysis performed using Image J software. 
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Discussion  
Little is known about the biological functions of EsxA and EsxB during 
Staphylococcus aureus pathogenesis. Missiakas's group demonstrated that the 
transposon mutants defective in EsxA and EsxB secretion show decreased 
virulence in an abscess model of staphylococcal infection indicating a key role of 
these two proteins in a kidney abscess formation [8]. The high conservation among 
the S. aureus clinical strains suggests their importance as virulence factors.  
Although the mechanisms of action of the two ortholologous proteins in 
Mycobacterium tuberculosis ESAT-6 (EsxA) and CFP-10 (EsxB) are very well 
characterized, the biological functions of the S. aureus counterparts during 
infection and the mechanisms of the secretion are not well defined.   
In this study we have analyzed different aspects of EsxA and EsxB proteins 
including expression, secretion and role during in vitro biofilm formation. 
A gene expression analysis, performed in different in vitro condition, showed that 
esxB is induced under selective conditions such as biofilm, and repressed in 
presence of serum. Both genes are more expressed in MRSA USA300 compared to 
MSSA Newman strain indicating differencies in regulation of the two proteins in 
diverse clinical strains. Expression analysis during in vitro infection of epithelial 
cells show and up-regulation 6h post infection suggesting that esxA and esxB could 
play a role in S. aureus intracellular infection.   
The development of a biofilm is a multistep process involving an initial attachment 
to human matrix proteins, a subsequent maturation phase characterized by 
intercellular aggregation and a final dispersal phase that involves the detachment of 
single cell or cell clusters by various mechanisms [4]. We found that esxB is 
significantly up-regulated in bacteria within biofilms. Consequently, employing 
isogenic mutants we observed that ∆esxB accumulated more biofilm in vitro at later 
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time point. In order to understand if EsxB had a direct role in biofilm formation, we 
analysed the differences in gene expression profile between WT and mutant strains. 
We observed that none of other staphylococcal genes were significantly differential 
expressed in the esxB mutant strain, indicating a potential direct role of this protein 
in biofilm. We still do not understand the precise role of EsxB in biofilms. 
However our hypothesis is that EsxB may be important in dissemination of 
biofilms so could play a role in the dispersal of staphylococcal biofilms being 
directly involved in biofilm detachment by affecting cell-cell interactions. It could 
act to destroy the biofilm matrix or it is also possible that EsxB has post-
translationally control on the secretion of proteins that may be involved in biofilm 
development. 
Interaction between the various components of the apparatus of secretion was also 
analyzed. While the mycobacterial EsxA and EsxB function as a heterodimer [15], 
the staphylococcal EsxA was crystallized as a homodimer, and there is no current 
evidence suggesting that the two proteins interact [16]. Unlike ESAT-6 and CFP-
10, EsxA and EsxB do not interact each other. In a very recent work using a 
biochemical approach to detect protein-protein interaction, EsxA and EsxB of S. 
aureus were reported to interact with different Ess substrates such as EsxC and 
EsxD respectivel[19]. We employed a Tandem Affinity Purification method (TAP) 
to identify any other interactors of S. aureus. It combines affinity purification and 
mass spectrometry analysis to identify the interactors. However our experiments 
performed on the total lysate of S. aureus did not reveal any interactions between 
Esx proteins. Hence as discussed earlier, the conditions used and the presence of 
tags on the proteins may have interfered with our analysis. 
Staphylococcal EsxA and EsxB are small secreted proteins that lack a canonical 
topogenic sequence. The secretion of EsxA and EsxB into culture medium during 
growth in vitro was previously demonstrated [8]. C-terminal signals were reported 
previously to mediate secretion of CFP-10 and other Esx locus encoded substrates 
Chapter 3 
 44 
secreted by mycobacterial ESX-1 system [15]. We show that the C-terminus of 
EsxA, that contains residues conserved in the Esx substrates, is required for 
secretion in vitro. While single or multiple changes in amino acids did not appear 
to affect secretion, a truncation of the C-terminus resulted in a significant decrease 
in secretion, as reported recently for secretion of another Ess substrate-EsxD [19]. 
This indicates that the C-terminus may control secretion by mediating interactions 
with other proteins.  
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Abstract 
The opportunistic pathogen Staphylococcus aureus is one of the major causes of 
healthcare-associated infections. S. aureus is primarily an extracellular pathogen, 
but recently it has been reported to invade and replicate in several host cell types. 
The ability of S. aureus to persist within cells has been implicated in resistance to 
antimicrobials and recurrent infections. However, few staphylococcal proteins that 
mediate intracellular survival have been identified. Here, we examine if EsxA and 
EsxB, substrates of the ESAT 6-like secretion system (Ess), are important during 
intracellular S. aureus infection. The Esx proteins are required for staphylococcal 
virulence but their functions during infection are unclear. While isogenic S. aureus 
esxA or esxB mutants are not defective for epithelial cell invasion in vitro, a 
significant increase in early/late apoptosis was observed in esxA mutant-infected 
cells as compared to wildtype. Impeding secretion of EsxA, by deleting C-terminal 
residues of the protein, also resulted in a significant increase of epithelial cell 
apoptosis. Furthermore, cells transfected with esxA showed an increased protection 
from apoptotic cell death. A double mutant lacking both EsxA and EsxB also 
induced increased apoptosis, but remarkably was unable to escape from cells as 
efficiently as the single mutants or wildtype. Thus, using in vitro models of 
intracellular staphylococcal infection, we demonstrate that EsxA interferes with 
host cell apoptotic pathways and, together with EsxB, mediates the release of S. 
aureus from the host cell. 
 
 
 
 
 
 
 
 
Chapter 4 
49 
 
Introduction 
Staphylococcus aureus (S. aureus) is a Gram-positive coccus that causes infections 
ranging from superficial skin lesions to serious conditions like pneumonia and 
endocarditis. S. aureus is also a major cause of hospital-acquired infections of 
surgical wounds and of indwelling medical devices. Staphylococcal infections, in 
particular systemic and chronic infections, place a major burden on healthcare 
systems worldwide (1, 2). Antibiotic resistance still remains a challenge in the 
management of staphylococcal infections, especially with the recent rise in 
methicillin and vancomycin resistant strains (MRSA and VRSA) (3, 4). During 
infection, S. aureus expresses a wide array of secreted and cell surface-associated 
virulence factors to evade immune responses by a variety of mechanisms such as 
promoting adhesion to host cells, binding proteins in blood or resisting immune cell 
attack (5-7). 
In addition to its armor of virulence factors, the capacity of S. aureus to 
successfully evade host defenses has been recently attributed to its ability to invade 
immune and non-immune cells. S. aureus is mainly an extracellular pathogen, but 
an accumulating number of studies have shown that it can invade and replicate in 
many types of non-phagocytic host cells in vitro (8). Clinical studies have reported 
the presence of intracellular staphylococci from nasal epithelial cells, indicating 
that this could serve as a reservoir for recurrent infections (9, 10). Although the 
intracellular presence of S. aureus during in vivo staphylococcal infection remains 
unclear, a transient, intracellular lifestyle potentially provides protection against 
exposure to antibiotics and host immune responses, as well as a favorable 
environment for the formation of resistant variants (11, 12). 
S. aureus possesses the Sec and Tat secretion systems, which presumably transport 
the majority of the known virulence factors (13, 14). A specialized ESAT-6 
secretion system (Ess), similar to Esx-1 secretion system described in 
Mycobacterium tuberculosis (Mtb) was also identified in S. aureus (15). Ess 
consists of 12 proteins, including EsxA and EsxB that are similar to the ESAT-6 
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and CFP-10 of Mtb. ESAT-6 (EsxA) and CFP-10 (EsxB) are well-characterized 
virulence factors of Mtb implicated in survival in macrophages, host cell lysis and 
dissemination (16-18). For the staphylococcal Esx proteins, mutants that failed to 
secrete EsxA and EsxB displayed defects in S. aureus abscess formation in mice, 
suggesting that these proteins are important during staphylococcal disease (15). 
Other Ess proteins such as EsaD were reported to be important for staphylococcal 
virulence, while EsaC was required for persistent staphylococcal infection in mice 
(19, 20). Importantly, to date no clear biological function has been attributed to the 
staphylococcal Esx proteins. 
The precise structure of the Ess secretion apparatus is currently not known. 
Structural analysis of EsxA suggests that this protein may act as a chaperone or as 
an adaptor protein to facilitate interactions with host receptor proteins (21). Co-
dependent secretion of Ess substrates has been reported, similar to that observed for 
mycobacterial substrates (15). C-terminal residues are important for interaction of 
the mycobacterial EsxB with other proteins of the apparatus and for secretion (22, 
23). Recently, a C-terminal motif (YxxxD/E) of the Ess substrate EsxD, was shown 
to be required for secretion of EsxA and EsaC (24). 
In this study we examine a potential intracellular role for the staphylococcal EsxA 
and EsxB, employing an in vitro cellular model of S. aureus infection. We 
demonstrate that EsxA interferes in S. aureus-induced apoptosis in human 
epithelial cells in vitro. This inhibitory effect is associated with the secretion of 
EsxA, which is mediated by C-terminal residues of the protein. Our data also 
suggest that EsxA and EsxB together affect the release of intracellular S. aureus 
from host cells. 
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Materials and Methods. 
Bacterial strains and growth conditions. S. aureus strain USA300 (lac) was used 
for all the experiments. Complemented S. aureus strains were grown in presence of 
chloramphenicol 10µg/ml. For infection experiments bacteria were grown in 
Tryptic Soy Broth (TSB) overnight (O/N) at 37°C, diluted 1/100 in fresh TSB and 
cultured until exponential phase of growth (A600= 0.6-0.7) and then re-diluted 
1/100 in DMEM supplemented with 10% fetal bovine serum (FBS). 
Construction of bacterial mutants. For deletion of esxA and esxB a 2kb DNA 
fragments flanking the esx genes were amplified by PCR and cloned into the 
Escherichia coli/S. aureus shuttle/suicide vector pKOR1 using previously 
described methods (25). The esxA and esxB double mutant was obtained by 
deleting esxA in the ∆esxB mutant. All mutants were confirmed by PCR using 
external primers of flanking regions and sequencing. For complementation of 
mutant strains, the full length esxA and esxB genes were amplified and cloned into 
plasmid pOS1CK, which was generated by cloning the P1 constitutive promoter of 
the sarA gene into the pOS1 plasmid. For complementing with both genes, esxB 
was cloned downstream of esxA in the pOS1CKesxA construct. esxA with site 
directed mutations were cloned into the episomal plasmid pOS1CK. For generation 
of fluorescent bacteria, pOS1CK-GFP was cloned into WT and ∆esxAB strains.  
Eukaryotic cell culture. Human lung epithelial cell line A549 (CCL-185™) was 
obtained from the ATCC and cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% heat-inactivated fetal calf serum (Biological 
Industries) and incubated at 37°C, 5% CO2. For cell passages, 100µg/ml primocin 
(Invivogen) was supplemented in the medium, whereas no antibiotics were used 
24h prior and during infection assays.  
S. aureus infection of eukaryotic cells. At 24h before infection 2x10
5
 cells/ml 
A549 cells were seeded in a 24-well plate (Nunc, Wiesbaden, Germany) so as to 
have 80% cell confluency. S. aureus cultures, as described above were diluted in 
DMEM-10 and added on A549 at an MOI of 7:1. After 2h of incubation, 
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extracellular bacteria were killed by adding 20µg/ml lysostaphin (Sigma Aldrich) 
for 30 min at 37°C. To remove lysostaphin and dead bacteria, cells were washed 
with growth medium once and, in the case of further incubation, fresh growth 
medium supplemented with 5µg/ml lysostaphin was added in each well. Infected 
host cells were trypsinized and lysed with cold water in a final volume of 1ml. 
Lysates were diluted with PBS and plated in serial dilutions on TSA plates to 
calculate the CFU/ml. 
Confocal Microscopy. For fluorescence microscopy, cells were grown in chamber 
slides with polylysine coating and infected with S. aureus as described above. After 
lysostaphin treatment, cells were rinsed once with warm culture medium and fixed 
for 15 min with 4% paraformaldehyde at room temperature (RT). For observing 
intracellular infections with Vancomycin-Bodipy FL staining (Molecular Probes), 
cells were incubated with 2µg/mlvancomycin-1% BSA in PBS at 4°C in the dark 
for 15 min, washed once. Phalloidin (Molecular Probes) at a dilution 1:40 was used 
for staining F-actin. For analysis, 60-150 cells were counted/field and at least 4 
fields were counted for each experiment. For microcolony visualization, samples 
were incubated with rabbit anti-staphylococcus at dilution of 1:1000 (ProSci), 
Alexa Fluor 488-labeled secondary antibodies (1:1000), together with biotinylated 
wheat germ agglutinin (1:500) and streptavidin-Alexa Fluor568 (1:1000) for 15 
min at RT. The images were acquired with the confocal microscopes Leica 
LSM700 and LSM710 and analyzed by Leica Confocal Software (Leica 
Microsystems, Heidelberg, Germany).  
Preparation and analysis of bacterial fractions. Bacterial lysates and supernatants 
were prepared as modification of described previously (26). Flow cytometry 
analysis. For analysis of apoptosis, cells were grown on 24-well plates and infected 
with S.aureus as described above. At various time points post infection, medium 
was aspired and 1x10
7
 cells were detached using cell dissociation Buffer 
(Invitrogen). Cells were washed once at 3000g, pelleted, resuspended in 50µl Aqua 
Live-Dead 1:500 (Invitrogen) and then incubated for 20 min in the dark at 4°C. 
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Cells were pelleted at 3000g, washed once with PBS and resuspended in 200µL 
Annexin-V (eBioscience) and incubated for 20 min in the dark at 4°C. The cells 
were washed, fixed with PFA 4% and resuspended in 150µl PBS. The double 
staining was analyzed by a FACS Canto II flow cytometer using the FlowJo 
software on a subpopulation of entire single cells selected from the initial 
population, based on the morphology. Each experiment was repeated at least three 
times. 
Expression of bacterial esxA in A549 cells. We constructed pesxA-EYFP by 
cloning the full length esxA gene upstream of and in frame with the EYFP of 
plasmid pEYFP-N1 (Clontech). For transfection of the A549 cells, 8x10
5
 cells/well 
were seeded on a 6-well plate O/N and transfected using Lipofectamine 2000 
(Invitrogen) using manufacturer’s protocols. After 6h, the medium was changed 
and 24h post transfection cells labeled with Aqua Live-Dead and Annexin-V. Cells 
were analyzed by flow cytometry selecting for cells that were positive for EYFP. 
Statistical analysis. A non-parametric, one way ANOVA Tukey’s or Dunnett’s 
multiple comparisons test at 95% confidence interval was applied to data in 
multiple groups, and a two tailed Mann Whitney U test was used for 2 groups. A 
P<0.05 was considered statistically significant.  
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Results 
EsxA modulates apoptosis in S. aureus infected cells. To study a potential role of 
EsxA and EsxB, two proteins encoded by the Ess locus of S. aureus (15), in the 
invasion and survival of human epithelial cells, isogenic single mutants ∆esxA and 
∆esxB, were generated in USA300. The absence of expression of esxA or esxB in 
the mutants was confirmed by qRT-PCR (Fig. S1A) and the analysis of the growth 
phenotypes of ∆esxA and ∆esxB in TSB medium showed no growth defects (Fig 
S1B). A549 epithelial cells were used for infection assays, given their high 
infection efficiency with wildtype (WT) USA300 (50-60% cells infected) at MOI’s 
from 1:1 to 10:1. A549 invasion assays performed comparing the esx mutants to the 
WT did not reveal any major differences in internalization efficacy (Fig. 1). 
Intracellular trafficking studies of the esx mutants by confocal microscopy showed 
presence of bacteria both in vacuoles and in the cytoplasm at 4h p.i., and mostly in 
the cytoplasm at 6h p.i. (data not shown). However, there were no significant 
differences in trafficking of the mutants as compared to WT. Interestingly, analysis 
of infected cells showed that very often the presence of intracellular bacteria in the 
cytoplasm was followed by actin polymerization, leading to rounding of infected 
cells. As compared with WT, higher numbers of cells infected with ∆esxA showed 
increased accumulation of polymerized actin (Fig. S2A), a phenotype linked with 
the earlier steps of apoptosis (27), as compared with WT-infected cells. This 
observation suggested that EsxA may play a role in host cell apoptosis during 
staphylococcal infection. 
To further investigate the potential role of EsxA in apoptosis, we performed flow 
cytometry analysis on cells infected with WT and the esx mutants at different time 
points after infection. Cells were stained with AquaLive-Dead that stains lysed 
cells (a marker of cell death) and Annexin-V that specifically binds to the 
phosphatidylserine (PS) exposed on the plasma membrane of apoptotic cells. 
Staining with Annexin-V showed an increased number of early and late apoptotic 
cells at 6h p.i. for ∆esxA-infected but not the ∆esxB-infected A549 cells (Fig. 2A, 
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B). As shown in the scatter plots, the cells that are infected by ∆esxA mutant 
consist of increased subpopulations of early (bottom right quarter of the scatter 
plot) and/or late apoptotic (top right quarter of the scatter plot) cells compared to 
WT-infected cells. The increase in apoptosis observed for the mutant was reversed 
upon episomal expression of esxA in the ∆esxA mutant, ∆esxApOS1CKesxA 
(∆esxA-esxA) (Fig. 2A, B). As reported previously, the WT-infected cells also 
showed an increase in apoptosis compared with uninfected cells (28, 29). These 
differences in the number of apoptotic cells were found to decrease at later time 
points (8h and 16h), possibly because during infection cells containing intracellular 
bacteria die and detach from the monolayer (data not shown). 
These data suggest that the EsxA protein may modulate S. aureus-induced 
apoptosis during epithelial cell infection in vitro. 
C-terminal residues are important for secretion of EsxA: impacting EsxA 
secretion affects EsxA-mediated modulation of apoptosis. As EsxA is a secreted 
protein, we wanted to test if preventing secretion of EsxA could also result in 
increased apoptosis. As the signal sequences controlling EsxA secretion are not 
known, we first identified the residues that are required for secretion of the protein 
in vitro. Based on the homology between Mtb and S. aureus Esx proteins, we 
identified the amino acids that are conserved at the C-terminus of the 
staphylococcal proteins, a region thought to be important for secretion of Esx 
proteins in mycobacteria (22). Leucine90, serine91 and glycine95 were conserved 
in both the staphylococcal Esx proteins and the mycobacterial EsxB (Fig. 3A). 
In an attempt to define targeting sequences responsible for mediating secretion by 
the Ess system, we studied effects of site-directed mutations and deletions at the C-
terminus of the EsxA protein. EsxA bearing mutations in three amino acids (L90A, 
S91A, and G95A) or with an 8 amino acid (a.a.) deletion was expressed episomally 
in the ∆esxA mutant to create strains ∆esxApOS1CKesxA-LSG (∆esxA-esxALSG) 
and ∆esxApOS1CKesxAtrunc (∆esxA-esxAT) respectively. Immunoblotting 
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analysis showed that the triple mutation in EsxA mildly reduced (by ∼25%) 
secretion of the protein into the culture supernatant (∆esxA-esxALSG) as compared 
with secretion of native EsxA (∆esxA-esxA). Truncation of the C-terminal tail of 
EsxA comprising the last 8 a.a. severely impaired secretion of the protein (by 
∼75%) (Fig. 3B). 
To understand if hindering secretion of EsxA affects cellular apoptosis, we 
investigated if the strains ∆esxA-esxALSG and ∆esxA-esxAT were able to reverse 
the increase in apoptosis induced by the ∆esxA mutant, as seen above with the 
∆esxA mutant complemented with native EsxA (∆esxA-esxA) (Fig. 2A, B). Flow 
cytometry analysis showed that the ∆esxA mutant expressing the truncated EsxA 
(∆esxA-esxAT) was able to induce more apoptotic cells when compared to the 
mutant expressing native EsxA protein (Fig. 3C) and had similar profile to the 
control i.e ∆esxA mutant transformed with empty plasmid (∆esxA-pOS1CK). On 
the other hand the ∆esxA-esxALSG strain did not show a similar increase in 
apoptosis; probably due to the minimal effects of the LSG mutation on EsxA 
secretion (Fig. 3B).  
Thus, these data suggest that impacting secretion of EsxA can affect the EsxA-
mediated modulation of host cell apoptosis in epithelial cells in vitro. 
EsxA delays apoptosis when expressed in the host cell. In order to further confirm 
that EsxA interferes with host apoptotic pathways, A549 cells were transfected 
with the plasmid pEYFP expressing full length esxA or truncated (8 a.a.) as N-
terminal fusions with EYFP (pesxA-EYFP). Using flow cell cytometry, we 
measured by Annexin-V and AquaLive-Dead staining the apoptotic subpopulations 
in the transfected cells (gated by expression of EYFP). The expression of full 
length esxA in the cytoplasm resulted in a 2.5-fold decrease of the number of 
apoptotic cells compared to the control cells transfected with the empty vector 
pEYFP (Fig. 4A). These data are in agreement with the results described above for 
the esxA mutant. Expression of esxA lacking the C terminal 8 a.a. on the other hand 
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did not induce a decrease in apoptosis, indicating that the C-terminal residues 
needed for secretion are not important in mediating apoptosis (Fig. S3). 
Staurosporine, a potent inducer of apoptosis, is known to induce caspase-dependent 
and caspase-independent apoptotic pathways (30). We tested if EsxA suppresses 
staurosporine-induced apoptosis. 24h after transfection with control plasmid 
pEYFP or pesxA-EYFP, cells were treated with 2.5µM staurosporine for 30min. 
Staurosporine-induced apoptosis, as measured by Annexin-V staining was 
significantly reduced in cells transfected with pesxA-EYFP, compared with the 
control pEYFP-transfected cells (Fig. 4B).  
The data in all support a role for the staphylococcal EsxA in interfering with cell 
apoptotic pathways. 
Esx proteins affect escape of bacteria from host cells. The mycobacterial 
counterparts EsxA and EsxB are known to form a heterodimer and also function 
together to cause host cell lysis (31, 32). Recent data have shown that EsxA and 
EsxB can interact with different Ess substrates, however do not interact directly 
each other (21, 24). To understand the effects of EsxA and EsxB taken together, we 
constructed a double mutant of esxA and esxB. As observed for the single mutants, 
∆esxAB was similar to WT for invasion into epithelial cells (data not shown). As 
observed for ∆esxA in Fig 2, ∆esxAB induced more apoptosis in epithelial cells 
(Fig. S4). Interestingly, colony counts from infected A549 cells showed a 
significant increase for intracellular ∆esxAB at later time point after cell invasion 
(16h p.i.) as compared to WT (Fig. 5A). Examination of cells by confocal 
microscopy revealed presence of more intracellular bacteria in epithelial cells 
infected with ∆esxAB as compared to the WT (Fig. 5B). The differences between 
WT and the double mutant were also confirmed using GFP-expressing S. aureus 
strains; cells containing more fluorescent bacteria were observed for the ∆esxAB-
infected as compared to WT-infected cells (Fig. 5C). 
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To understand if the ∆esxAB strain was accumulating within cells as a result of its 
inability to exit cells, we used a continuous infection assay, where infected A549 
monolayers were first treated with lysostaphin to remove extracellular bacteria, but 
thereafter incubated in medium without lysostaphin for different time periods. 
Bacteria were seen to exit cells and progressively form extracellular bacterial 
aggregates on the cell layer. After 9h post infection we observed the formation of 
several such S. aureus ‘microcolonies’ by immunofluorescence staining of cells 
infected with WT, ∆esxA and ∆esxB, but very few for cells infected with the double 
mutant ∆esxAB (Fig. 6). Equal infection efficiency in this continuous infection 
assay was confirmed for all strains by quantitating intracellular counts after 2h 
(data not shown). Again, the esxAB mutant was able to eventually exit cells at later 
times as seen for the WT.  
These results may suggest that in our in vitro infection assay, EsxA and EsxB 
together modulate cellular escape of S. aureus. 
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Discussion  
The human pathogen S. aureus has been shown to invade and survive in a range of 
host cells in vitro. (8, 12, 33). Despite several studies describing intracellular 
staphylococcal infection, there is very little understanding of the bacterial factors or 
the mechanisms involved in intracellular survival of S. aureus. Our data show that 
EsxA, a protein secreted by the specialized staphylococcal Ess secretion system, 
modulates host cell survival by interfering with apoptotic pathways. To our 
knowledge this is the first description of staphylococcal factor that has an anti-
apoptotic function in epithelial cells. Our data also support intracellular functions 
for the staphylococcal Esx proteins in cellular models of infection. 
The interplay between bacterial virulence factors and host cell proteins is of utmost 
importance for a successful bacterial infection and staphylococcal infection is no 
exception to the rule. In order to persist in the hostile environment of the host cell, 
invading pathogens have developed various mechanisms to survive intracellularly, 
e.g. by inhibiting the lysosomal killing or by fine-tuning cell mechanisms such as 
apoptosis or autophagy (34, 35). It is known that apoptosis, a well-known 
mechanism of cell death, is induced by intracellular S. aureus (29, 36, 37). The 
staphylococcal toxin, alpha hemolysin (Hla) was reported to induce apoptosis upon 
intracellular staphylococcal infection (37). The apoptotic pathways affected by S. 
aureus appear to depend on the strain and host cell type used and several studies 
argue for or against the employment of molecules such as caspases (28, 38, 39) or 
calcium, (40) in S. aureus-induced apoptosis in epithelial cells. On the other hand, 
as seen for many other bacteria, S. aureus may also be able to block apoptosis. 
Although an anti-apoptotic effect of S. aureus has not been demonstrated as yet, S. 
aureus was recently reported to induce anti-apoptotic factors in epithelial cells (41). 
During staphylococcal infections, EsxA alone and/or with other Ess effectors, may 
transiently block cell apoptosis induced by extracellular staphylococci or by other 
staphylococcal proteins, to allow for intracellular replication of the bacteria. 
Indeed, it has been shown in other pathogens, such as Helicobacter pylori and 
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enteropathogenic E.coli (42, 43) that bacterial proteins can have both pro- and anti-
apoptotic activities and that bacterial anti-apoptotic factors are active in the host 
cell cytoplasm. S. aureus, like other bacterial intracellular pathogens, is capable of 
manipulating the host cell to its advantage.  
EsxA and EsxB, substrates of a novel ESAT-6 like secretion (Ess) system, are 
located in the same locus, however are separated by 6 other genes (15). EsxA has 
been reported to be regulated by sigma factor B and σB-controlled SpoVG, and is 
expressed as a single transcript, while we do not know how EsxB is regulated (44). 
Secretion of EsxA and EsxB into culture medium during growth in vitro was 
demonstrated previously, with mutation of EsxB affecting secretion of EsxA and 
vice versa (15). Very recent work further reports that deletions in either gene also 
affects secretion of additional Ess substrates, EsxC and EsxD (24). EsxA and EsxB 
were reported to interact with different Ess substrates such as EsxC and EsxD 
respectively (24). Hence it is not surprising that EsxA and EsxB mutants behave 
differently in terms of modulating apoptosis. EsxA and EsxB may affect stability 
and secretion of specific subsets of Ess substrates inside cells.  
C-terminal residues were reported previously to mediate secretion of EsxB (CFP-
10) and other Esx locus encoded substrates secreted by mycobacterial Esx-1 and 
Esx-1 paralogs (22, 23). We show that the C-terminal tail of EsxA which contains 
residues conserved in mycobacterial and the staphylococcal Ess substrates, EsxA 
(and EsxB), is important for secretion of EsxA in vitro. The effect of these residues 
on the secretion of other Ess substrates was not examined in this study, however we 
believe that this could be the case as reported recently (24). Also, secretion of EsxA 
is not completely abolished, hence there are likely to be other residues or 
interactions governing secretion. Defective secretion of EsxA mimics the increase 
in apoptosis seen for the ∆esxA mutant. This suggests that secretion of EsxA is 
important for the EsxA-mediated apoptosis. However, we are yet to demonstrate 
directly the intracellular secretion of this protein. 
As discussed above, disrupting secretion of EsxA may affect EsxA-dependent Ess 
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substrates. However, our transfection studies indicate that EsxA may directly 
mediate an anti-apoptotic effect in the host cytoplasm. EsxA lacking the C-terminal 
8 a.a. was not important for cellular effects, indicating that the any interactions with 
host or bacterial factors may involve alternate regions of the protein. EsxA may 
function by either blocking one of the caspase-mediated pathways or by imitating 
or inducing host anti-apoptotic factors, such as Bcl2. Preliminary analyses of hla 
expression or secretion in the esxA mutant showed no changes (also as shown in 
Fig 3B), indicating no direct interactions between Hla and EsxA. Further 
investigations of the S. aureus-induced cell death pathways intercepted by EsxA 
are currently ongoing and will reveal molecular mechanisms involved in 
subversion of host cell death. 
In other pathogens, an important step in bacterial dissemination, after intracellular 
replication, is the bacterial exit from the host cells. Previous studies have 
demonstrated that staphylococcal factors such as PSMs and leukocidins may affect 
bacterial escape from neutrophils (45, 46). The roles of these factors in non-
immune cells are at present not clear. While both ∆esxA and ∆esxAB mutants show 
increased apoptosis, in continuous in vitro invasion assays the exit of bacteria from 
epithelial cells is affected only when both proteins are absent. The mycobacterial 
EsxA and EsxB function as a heterodimer (31), but recently the mycobacterial 
EsxA alone was demonstrated to mediate lipid membrane lysis (47). The 
staphylococcal EsxA was crystallized as a homodimer, and there is no current 
evidence suggesting that the two proteins directly interact (21). We propose two 
possible explanations for our results with the double mutant: 1. EsxA and EsxB 
directly mediate cell lysis, in association with host proteins in a multiprotein 
complex, 2. EsxA and EsxB modulate secretion of specific subsets of other Ess 
effectors which mediate cell lysis; deletion of both proteins results in total loss of 
all required effectors. 
The orthologous Esx proteins in mycobacteria have been implicated in several 
aspects of pathogenesis including survival of mycobacteria in macrophages, 
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granuloma formation, induction of apoptosis and autophagy, phagosomal rupture 
and host cell lysis (16, 48). Although other Gram-positive bacteria such as Listeria 
monocytogenes contain orthologs, their functions are unclear (49, 50). The EsxA 
proteins from S. aureus and Mtb demonstrate only 20.8% identity (15), although 
they show structural similarities (21). It is very intriguing that the Esx proteins 
seem to have an intracellular role in Mtb and S. aureus, two very diverse 
pathogens. The mechanisms, by which they affect intracellular survival, however, 
appear different. Our data suggest that staphylococcal Esx proteins are not involved 
in avoiding phagosomal lysis, as indicated by lack of differences in the cytoplasmic 
vs vacuolar bacteria in infected epithelial cells, but may be involved in lysing the 
host cell. The staphylococcal proteins do not appear to affect the survival of the 
bacteria within the cell per se, as bacterial numbers by colony counts (Fig. 1) and 
by microscopy (data not shown) appear to be unaltered. Such differences with Mtb 
may reflect differences between the pathogens, but could also be attributed to the 
cell type under study i.e. macrophages vs epithelial cells. Both pathogens however 
may use the host cell as a niche to replicate and disseminate, with a key role for 
Esx proteins. Indeed, for S. aureus, the relevance of intracellular bacteria to 
infection and the role of the Esx proteins in modulating this remains to be 
demonstrated. 
The facultative intracellular pathogen, S. aureus may use the host cell to escape 
unfavorable extracellular environments. This intracellular phase may play a key 
role in determining persistence of the bacteria within an infected tissue. Esx 
proteins have been implicated in persistence within abscesses in infected mice (19). 
Based on our data from an in vitro model of infection, we propose that the Esx 
proteins by delaying host cell death and controlling bacterial exit from host cells, 
may facilitate persistence and spread of the pathogen in the infected host. Future 
studies on the how the intracellular effects of these proteins contribute to virulence 
will clarify their role during infection. 
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Figures 
 
 
Fig. 1  WT and mutant strains do not show any differences in cell invasion 
Invasion of WT and esx mutants into A549 epithelial cells 2h p.i. A549 cells were 
infected as described in Methods. 2h p.i. Extracellular bacteria were removed with 
lysostaphin treatment, cells were lysed and intracellular bacteria were quantitated 
by colony counts.  
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Fig. 2 EsxA modulates host cell apoptosis 
A Representative flow cytometry scatterplots depicting the early apoptotic (bottom 
right quadrant), late apoptotic (top right quadrant) and dead cells (top left quadrant) 
6h p.i. The numbers in the plots represent the percentage of gated A549 cell 
populations in each quadrant. B Flow cytometry analysis of S. aureus-infected 
A549 cells. Quantitation of apoptotic cells using flow cytometry for A549 cells 
infected by WT, ∆esxA, ∆esxB and ∆esxA-esxA at 6h p.i. Cells were stained with 
AquaLive-Dead 1:500, for the detection of lysed cells, and with Annexin V-FITC 
for the detection of apoptotic cells. Graphs represent percentage of early and late 
apoptotic cells in the parent population for the mutant-infected cells in relation to 
the WT, which was set at 100%. * indicates significant differences using a one way 
ANOVA with a Tukey’s multiple comparisons test (P< 0.05). The data presented 
are the mean of 3 independent experiments +/- s.d.  
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Fig. 3 C-terminal residues are important for secretion of EsxA: impeding 
EsxA secretion affects EsxA-mediated modulation of apoptosis 
A Alignment of amino acid (a.a) sequence of M. tuberculosis and S. aureus EsxA 
and EsxB proteins. In red are shown the high conserved amino acid residues that 
were replaced with alanine and a blue line indicates the 8 a.a deleted in the 
truncated EsxA protein. B Immunoblotting analysis of total extracts (TE) and 
supernatants (SN). Proteins in each fraction were precipitated with TCA, separated 
on SDS-PAGE, and detected by immunoblotting with anti-EsxA and anti-
Hemolysin (loading control). Loading was normalized by OD600 of bacterial 
culture. The graph shows the densitometry analysis performed using Image J 
software. C Flow cytometry analysis of apoptotic A549 cells infected with esxA 
mutant expressing native or mutant forms of EsxA. At 6h p.i. cells were dissociated 
and stained with AquaLive-Dead and Annexin V-FITC. The graph represents 
percentage of early and late apoptotic cells induced by the esxA mutant containing 
empty vector (∆esxA-pOS1CK) or the different mutant forms (∆esxA-esxAT, 
∆esxA-esxALSG) in relation to the esxA mutant expressing native esxA (∆esxA-
esxA) (set at 100%). Data are the mean of 3 independent experiments +/- s.d. * 
indicates significant differences using a one way ANOVA Tukey’s multiple 
comparisons test (P< 0.05). 
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Fig. 4 esxA interferes with apoptosis when expressed in the host cell 
A Flow cytometry analysis of apoptotic A549 cells transfected with esxA. 24h post 
transfection cells were dissociated and then stained with AquaLive-Dead and 
Annexin V-APC. The percentage of apoptotic cells (early and late apoptotic cells) 
was measured in the subpopulation bearing EYFP, i.e. transfected cells. Data are 
shown as a percentage of cells transfected with the control vector. Data are the 
mean of 3 independent experiments +/- s.d. * indicates significance by a two-tailed 
Mann Whitney test. B Flow cytometry analysis of apoptosis after treatment with 
staurosporine. 24h post transfection, A549 cells transfected with the plasmid 
pesxA-EYFP were treated with 2.5 mM staurosporine for 30 min, followed by 
AquaLive-Dead and Annexin V-APC staining. The percentage of apoptotic cells 
was measured in the subpopulation of transfected cells expressing EYFP. Data are 
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the mean of 3 independent experiments +/- s.d. * indicates significant differences 
using a one way ANOVA Dunnett’s multiple comparisons test (P< 0.05). 
 
 
Fig. 5 Increased numbers of intracellular bacteria in epithelial cells infected 
with ∆esxAB  
A Colony counts of intracellular WT, single and double mutants for the Esx 
proteins from A549 epithelial cells infected for 16h. A 5-fold increase can be seen 
between the WT and the double mutant. ** indicates significant differences by one 
way ANOVA with a Tukey’s multiple comparison test (P<0.001). Data are 
representative of 3 independent experiments. B Confocal microscopy of A549 
infected with WT or ∆esxAB after 16h infection. Intracellular bacteria were stained 
with vancomycin-BODIPY (green) and cells were stained with phalloidin (red). C 
Representative images (10X) of A549 cells with intracellular fluorescent (GFP-
expressing) WT and ∆esxAB. The white arrows indicate the intracellular bacteria.  
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Fig. 6 The staphylococcal EsxA and EsxB proteins may mediate bacterial 
release from infected cells  
Confocal microscopy analysis of A549 cells continuously infected by WT and 
mutant strains 9h 30min p.i.. Extracellular bacterial microcolonies and bacteria 
exiting infected dying cells can be seen on the cell layer (white arrows). Very few 
microcolonies were observed for the ∆esxAB. Bacteria were stained with anti-S. 
aureus (green) and cells were stained with wheat germ agglutinin (WGA) (red). All 
the images are representative of at least 3 independent infection experiments. The 
white arrows indicate bacterial ‘microcolonies’ outside epithelial cells. 
 
 
 
 
 
 
 
 
 
Chapter 4 
77 
 
Supplementary Figures 
 
 
 
Fig. S1 Expression analysis of esx deletion mutants and growth curves. 
A Expression analysis of esxA and esxB genes in USA300 WT strain and in 
different esx mutants by quantitative real-time PCR (qRT-PCR). Relative 
quantification was performed using 16S rRNA as internal control.  B Growth curve 
in TSB medium does not reveal any growth defects. 
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Fig. S2 esxA mutant is not defective for invasion, but induces more actin 
polymerization. 
A Confocal microscopy of A549 cells infected by the WT and the esx mutant 
strains ∆esxA and ∆esxB 4h p.i. Vancomycin-Bodipy-FL stains S. aureus wall, 
while phalloidin stains F-actin. Polymerized actin (condensed form) can be 
observed as brightly stained cell membranes on rounded cells (white arrows). B 
The graph shows quantitation of rounded infected cells with cell membranes 
bearing polymerized actin for the WT and esx mutant-infected cells. Data are 
representative of 3 independent experiments. * indicates significant differences, 
one way ANOVA, Tukey’s multiple comparisons test P<0.05.  
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Fig. S3 Flow cytometry analysis of apoptotic A549 cells transfected with 
truncated esxA  
24h post transfection cells were dissociated and then stained with Aqua Live-Dead 
and Annexin V-APC. The percentage of apoptotic cells (early and late apoptotic 
cells) was measured in the subpopulation bearing EYFP, i.e. transfected cells. Data 
are shown as a percentage of cells transfected with the control vector. Data are 
from one representative experiment 
 
 
Fig. S4 ∆esxAB mutant induces more apoptosis in epithelial cells compared to 
WT. 
Quantitation of apoptotic cells using flow cytometry for A549 cells infected by WT 
and ∆esxAB strain at 6h p.i. Cells were stained with Aqua Live-Dead (1:500), for 
the detection cell dead, and with Annexin V-FITC for the detection of apoptotic 
cells. Data are the mean of 3 independent experiments +/- s.d. * indicates 
significant differences using a one tailed Mann Whitney test (P< 0.05). 
Chapter 5 
80 
 
Conclusions 
The human pathogen Staphylococcus aureus is responsible for the vast majority of 
healthcare-associated infections worldwide [5]. Over the past 30 years, S. aureus 
strains have acquired resistance to different antibiotics, most notably β-lactam 
compounds (MRSA, methicillin-resistant S. aureus) [6]. In the USA, MRSA strains 
are isolated in more than 60% of nosocomial infections and are also a frequent 
cause of community-acquired disease. The recent emergence of vancomycin-
resistant MRSA strains has been viewed as testimony for the possible return to a 
pre-antibiotic era [8]. For these reasons the treatment of S. aureus infections is 
becoming problematic.   
The manifestations of staphylococcal diseases vary greatly, ranging from minor 
skin infections to life threatening pneumonia, septicemia and endocarditis. 
Depending on the body site and time of infection, S. aureus virulence factors are 
known to be differentially expressed, thus posing a significant challenge to targeted 
vaccine development [13].  
The diverse immune evasion strategies exhibited by S. aureus are well known. S. 
aureus can dwell in niches that are out of reach of normal humoral responses, such 
as in biofilms [54] and there is recent evidence that auxotrophic small-colony 
variants of S. aureus may persist intracellularly. This, perhaps transient, 
intracellular lifestyle may provide protection against exposure to antibiotics and 
host immune responses, as well as a favorable environment for the formation of 
resistant variants [61, 62]. A major future task is to find new and effective 
treatment for S. aureus infections. More specifically, there is a pressing need to 
identify new therapeutic strategy against S. aureus. To overcome the spectrum of 
diseases caused by this pathogen, a vaccine should ideally target virulence factors 
expressed in different stages and types of disease as well as those factors involved 
in immune evasion.  
S. aureus pathogenesis is multifactorial and depends on the expression of different 
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secreted and surface exposed proteins of S. aureus. Therefore, a better 
understanding of which genes and proteins are differentially expressed during 
pathogenesis and infection is necessary to understand the increased persistence and 
resistance of S. aureus. Thus, secreted proteins are critical in mediating virulence. 
Recently, a Type VII secretion systems have been described for several Gram-
positive bacteria including S. aureus (Ess secretion-system) [39, 43]. These 
secretion systems have been best studied in mycobacteria, where one such Type 
VII locus, the ESX-1 was shown to be important in virulence and granuloma 
formation [45]. 
EsxA and EsxB, virulence factors secreted by the Ess system are well conserved 
across clinical S. aureus strains and are currently being considered as potential 
vaccine candidates. The structurally similar M. tuberculosis Esx proteins have 
previously been successfully used to engineer new vaccines for TB since in the 
current BCG vaccine the ESX-1 locus is deleted. 
Although esxA and esxB genes are located in the same locus and are in the same 
gene clusters, it appears that they are regulated in different way and in contrast to 
the M. tuberculosis ESAT-6 and CFP-10 genes, they are not co-transcribed. The 
staphylococcal EsxA has been reported to be regulated by sigma factor B and σB-
controlled SpoVG, and is expressed as a single transcript, while we do not know 
how EsxB is regulated [52]. While the mycobacterial Esx proteins are important in 
several host-associated functions such as cell survival and granuloma formation 
little is known about staphylococcal Esx proteins during pathogenesis. The Esx 
proteins are believed to be crucial for bacterial persistence in a staphylococcal 
abscess[39]. 
During my study I have analyzed different aspects of these proteins including 
expression, secretion and role during in vitro infection. We characterized the 
expression of esxA and esxB in representative methicillin sensitive (MSSA)-
Newman and resistant S. aureus (MRSA)-USA300 isolates under in vitro 
conditions.  Although the genes are completely conserved, Esx proteins were 
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expressed and secreted to different extents in these two strains. Differences in the 
expression showed that both genes are more expressed by MRSA USA300 strain 
and this suggests that the regulation of expression or secretion of these proteins 
may differ in different strains of S. aureus. The gene expression analysis, 
performed during different in vitro conditions, indicate that these proteins are 
induced under selective conditions. A quantitative real time results showed that 
esxA and esxB are switched on during late growth phase in a rich medium and are 
little down-regulated in particular stress conditions as in presence of serum. 
Furthermore, these genes are modulated in biofilms and during intracellular 
infection that are likely to occur during infection. An induction of esxB expression 
was detected both during biofilm formation and after infection, while a mild 
increase of esxA transcript levels was detected intracellularly.  
In order to better characterize the biological function of these two virulence factors, 
we made single unmarked deletion mutants in two relevant clinical strains, 
Newman and USA300. Employing isogenic mutants we observed that ∆esxB 
accumulated more biofilm in vitro. Using expression microarray approaches to 
investigate changes in the transcriptome we observed that none of other 
staphylococcal genes were significantly differential expressed in the esxB mutant 
comparing to WT strain, indicating a potential direct role of this proteins in 
biofilms. Altought we do not understand the precise role of EsxB in biofilms, we 
speculate that EsxB may be important in dissemination of biofilms.  
Clinical studies have reported the presence of intracellular staphylococci from nasal 
epithelial cells, indicating that this could serve as a reservoir for recurrent 
infections [60]. Despite several studies describing intracellular staphylococcal 
infection in vitro, there is very little understanding of the bacterial factors or the 
mechanisms involved in intracellular survival of S. aureus. In this study we 
investigate the biological role of EsxA protein during intracellular infection of 
epithelial cells and we show that EsxA modulates apoptosis, a well-known 
mechanism of cell death. An isogenic esxA mutant induced more apoptosis 
Chapter 5 
83 
 
compared with WT in S. aureus infected epithelial cells and expressing EsxA 
within the cells resulted in delayed host cell apoptosis. While the staphylococcal 
toxin, alpha hemolysin (Hla) was reported to induce apoptosis upon intracellular 
staphylococcal infection[70]. As seen for many other bacteria, S. aureus may be 
also able to block apoptosis during in vitro infection of epithelial cells, thus 
allowing efficient replication of bacteria.  
Another aspect that was studied was the mechanisms underlying secretion via the 
Ess apparatus. While the homologus mycobacterial EsxA and EsxB function as a 
heterodimer [49] the staphylococcal EsxA was crystallized as a homodimer, and 
there is no current evidence suggesting that the two proteins interact each other 
[51]. On the contrary to what is already known for mycobacterial Esx proteins, the 
interactions between the various Ess components have not yet been mapped 
completely. Recent work further reports that deletions in either gene also affects 
secretion of additional Ess substrates, EsxC and EsxD. EsxA and EsxB were 
reported to interact with different Ess substrates such as EsxC and EsxD 
respectively[53]. In order to detect which are the other proteins involved in these 
interactions, we employed a tandem affinity purification method (TAP). TAP-
based purification in combination with mass spectrometry was used to detect 
specific interactions in various systems. Use of tagged proteins expressed by S. 
aureus will allow detection of any native bacterial proteins. The pull down 
experiments did not revealed any interaction between Esx proteins during the in 
vitro growth. This may be due to the possibility that the tags at the C- or the N-
terminus of the protein interfere in interactions. However we cannot exclude that 
the multiprotein complex acts during alternate more optimal conditions. It is 
possible that the proteins function together in a multiprotein complex with other 
host and/or staphylococcal proteins during infection.  
Co-dependent secretion of Ess substrates has been reported, similar to that 
observed for mycobacterial substrates with mutation of EsxB affecting secretion of 
EsxA and vice versa [39]. The signal sequence that mediates the Esx secretion in S. 
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aureus is not known. In an elegant series of studies in M. tuberculosis was reported 
that C-terminal residues are important for interaction of the mycobacterial EsxB 
with other proteins of the apparatus and for secretion [49]. Recently, a C-terminal 
motif (YxxxD/E) of the Ess substrate EsxD, was shown to be required for secretion 
of EsxA and EsaC [53]. Based on the homology between the S. aureus and M. 
tuberculosis Esx proteins we identified the high conserved residues that could have 
a functional role in secretion. The truncation of C-terminal tail of EsxA protein, 
which contains residues conserved in at least the Ess substrates EsxA and EsxB, 
was shown to be required for secretion in vitro and during in vitro intracellular 
infection. 
The studies from my PhD wished to extend the scientific knowledge about the 
functional role of two key staphylococcal virulence factors: EsxA and EsxB, in 
order to define their relevance in S. aureus pathogenicity as well as their 
importance as vaccine candidates. 
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